On December 22, 2021, HLN released a new version (v1.33.1) of the Immunization Calculation Engine (ICE) in support of updates to the COVID-19 vaccine. ICE is a state-of-the-art open source software system that provides clinical decision support for immunizations for use in Immunization Information Systems (IIS), Electronic Health Record (EHR), and Personal Health Record (PHR) Systems.
Version 1.33.1 includes the following additions and updates. Please see the Release Notes for details.
- COVID-19 Booster Dose rules - Updated and added additional rules for patients who completed Pfizer 2-dose series, Moderna 2-dose series, Janssen 1-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine.
- Booster Dose Minimum Age has been updated to 16 years to support new CDC recommendation that 16-17 year olds "may" receive a Pfizer booster.
- COVID-19 Additional Dose rules - Updated and added additional rules for patients who completed Pfizer 2-dose series, Moderna 2-dose series, Janssen 1-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine.
- New COVID-19 vaccine (CVX 217) - Added support and logic
- Note - CVX 217 is a new Pfizer formulation for ages 12+ under EUA; can be used in the same way as CVX 208
- Pfizer 2-dose series
- Updated Absolute Minimum Intervals between Dose 1 and Dose 2
- Moderna 2-dose series
- Updated Absolute Minimum Intervals between Dose 1 and Dose 2
- Updated Absolute Minimum Age for Dose 1
- Updated Absolute Minimum Age for Dose 2
- Updated Minimum Age for Dose 2
- Updated Routine Age for Dose 2
This release includes an important security update. We strongly recommend that all users and service providers update their running instances of ICE to version 1.33.1 as soon as possible. Each new release of ICE contains important forecaster logic updates and bug fixes.
Plans for COVID-19 Support in ICE
Once a vaccine has been approved for use by the FDA (either Expanded Access, EUA, or full licensure), the Advisory Committee on Immunization Practices (ACIP) will hold an emergency meeting and publish recommendations in a very quick time frame (i.e., days). HLN intends to release a version of ICE that includes updated COVID-19 forecasting as early as possible. The initial release will contain COVID-19 logic that is known at the time of the release. As additional, relevant information on COVID-19 becomes available from official sources, HLN will continue to release additional versions of ICE, at appropriate times.
If you have any questions, comments or suggestions, please e-mail us at [email protected].